Get my own profile
Public access
View all8 articles
0 articles
available
not available
Based on funding mandates
Co-authors
Peter GreasleyEarly Clinical Development, AstraZenecaVerified email at astrazeneca.com
Sidney AuerbachRutgers UniversityVerified email at biology.rutgers.edu
Cecilia WikellTeam Leader/Associate Principal Scientist, RIA iMed, AstraZenecaVerified email at astrazeneca.com
Johanna Andersson-AssarssonSahlgrenska Academy at University of GothenburgVerified email at medic.gu.se
Markku PeltonenProfessor, National Institute for Health and Welfare (THL), FinlandVerified email at thl.fi
Tomas DrmotaCONTIPROVerified email at contipro.com
Nils-Olov HermanssonAstraZenecaVerified email at ekompetens.se
Viveka HillegaartDocent i Zoologi,SLUVerified email at slu.se
Bo SöderpalmAddiction Biology Unit, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, UniversityVerified email at neuro.gu.se
Per-Arne SvenssonPerfessor in Medical ScienceVerified email at medic.gu.se
Hans NissbrandtProfessor, Dept of Pharmacology, Univ of GothenburgVerified email at gu.se
Stephane MilanoDirector Preclinical & PharmacologyVerified email at alz-pharma.com
Kajsa SjöholmAssociate Professor, Gothenburg UniversityVerified email at medic.gu.se
Annika ÅstrandRIA iMed, AstraZenecaVerified email at astrazeneca.com
Alonso FernándezProfesor titular, Departamento de Farmacobiologia, Cinvestav Sede SurVerified email at cinvestav.mx
Mohammad Bohlooly-YDirctor AstraZenecaVerified email at astrazeneca.com
Erik SundströmSenior Researcher, Karolinska InstitutetVerified email at ki.se
Vicente Martínez PereaProfessor of Physiology, Universitat Autònoma de BarcelonaVerified email at uab.es
Richard McQuadeVerified email at ncl.ac.uk
Göran EngbergProfessor of PharmacologyVerified email at ki.se